首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease.
【24h】

Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease.

机译:与慢性移植物抗宿主病患者相比,光耗对CD4 + Tregs和CD4 +效应T细胞有不同的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Even the most potent immunosuppressive drugs often fail to control graft-versus-host disease (GVHD), the most frequent and deleterious posttransplantation complication. We previously reported that photodepletion using dibromorhodamine (TH9402) eliminates T cells from healthy donors activated against major histocompatibility complex-incompatible cells and spares resting T cells. In the present study, we identified photodepletion conditions selectively eradicating endogenous proliferating T cells from chronic GVHD patients, with the concomittant sparing and expansion of CD4(+)CD25(+) forkhead box protein 3-positive T cells. The regulatory T-cell (Treg) nature and function of these photodepletion-resistant cells was demonstrated in coculture and depletion/repletion experiments. The mechanism by which Tregs escape photodepletion involves active P-glycoprotein-mediated drug efflux. This Treg-inhibitory activity is attributable to interleukin-10 secretion, requires cell-cell contact, and implies binding with cytotoxic T-lymphocyte antigen 4 (CTLA-4). Preventing CTLA-4 ligation abrogated the in vitro generation of Tregs, thus identifying CTLA-4-mediated cell-cell contact as a crucial priming event for Treg function. Moreover, the frequency of circulating Tregs increased in chronic GVHD patients treated with TH9402 photodepleted cells. In conclusion, these results identify a novel approach to both preserve and expand Tregs while selectively eliminating CD4(+) effector T cells. They also uncover effector pathways that could be used advantageously for the treatment of patients with refractory GVHD.
机译:即使是最有效的免疫抑制药物,也常常无法控制移植物抗宿主病(GVHD),这是最常见,最有害的移植后并发症。我们先前曾报道,使用二溴莫罗丹(TH9402)进行光耗竭可消除来自健康供体的T细胞,这些供体针对主要组织相容性复合物不兼容的细胞而活化,并保留了静止的T细胞。在本研究中,我们确定了光消耗条件,有选择地根除慢性GVHD患者的内源性增殖T细胞,并伴随着CD4(+)CD25(+)前叉盒蛋白3阳性T细胞的保留和扩增。这些抗光耗尽性细胞的调节性T细胞(Treg)性质和功能在共培养和耗尽/补充实验中得到了证明。 Treg逃逸光耗竭的机制涉及活性P糖蛋白介导的药物外排。这种Treg抑制活性可归因于白介素10的分泌,需要与细胞接触,并暗示与细胞毒性T淋巴细胞抗原4(CTLA-4)结合。防止CTLA-4的连接消除了Tregs的体外产生,因此将CTLA-4介导的细胞间接触确定为Treg功能的关键引发事件。此外,用TH9402光耗尽细胞治疗的慢性GVHD患者的循环Treg频率增加。总之,这些结果确定了一种既保留和扩展Tregs又选择性消除CD4(+)效应T细胞的新颖方法。它们还揭示了可以有利地用于治疗难治性GVHD患者的效应子途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号